Gallbladder cancer is a highly aggressive cancer with a poor prognosis, and most patients are diagnosed too late for effective treatment. A study published in Nature Gene Therapy has uncovered new insights into a protein called BRD9, which could offer hope for better treatment options.
The researchers found that BRD9 levels are significantly higher in gallbladder cancer tissues compared to healthy ones. Patients with higher BRD9 levels also tended to have worse outcomes. By reducing BRD9 in lab experiments, the scientists were able to slow down the growth of cancer cells.
What’s especially promising is that when BRD9 was blocked with a compound called I-BRD9, it effectively inhibited the cancer cells without causing major toxic side effects. The study also revealed that BRD9 seems to play a role in activating the PI3K-AKT pathway, which is linked to cell survival in many cancers. By blocking this pathway, BRD9 inhibition slowed cancer growth.
While more research is needed, these findings suggest that targeting BRD9 could be a potential new approach for treating gallbladder cancer, which currently has very limited options for patients.